Statistical PK/TK Analysis

Offering full bioanalytical and PK/TK support for all stages of drug development.

Resolian’s team of pharmacokineticists has many years of experience carrying out pharmacokinetic (PK) and toxicokinetic (TK) analysis for all stages of drug development, providing you expertise, flexibility and quality.

Reach out to us directly to learn more about Resolian’s Statistical PK Analysis services.

Support for Pre-Clinical and Clinical Studies

Resolian uses industry-standard Phoenix WinNonlin for non-compartmental analysis, giving you access to a complete bioanalytical and pharmacokinetic/toxicokinetic (PK/TK) service to support your pre-clinical GLP toxicology and clinical studies.

Comprehensive standard operating procedures (SOPs), validated software systems and full QA facilities ensure regulatory compliance.

Planning

Pharmacokinetic parameters, methods of calculation and specific reporting requirements are set out in a detailed GLP phase plan or analytical project plan. Plans for regulated studies are audited by Resolian’s Quality Assurance department.

Reporting

Resolian’s reports contain high-quality tables, figures and listings along with interpretation and conclusions to aid in decision-making. Resolian also offers fast-turnaround interim reporting in support of dose escalation decisions for first-in-human studies.

Standalone Service

Resolian offers a standalone service performing PK/TK analysis on data generated outside of Resolian.

Data Management

Resolian can provide data in bespoke formats to meet your exact reporting needs. Resolian’s dedicated Data Management team provides data transfers and reporting to Clinical Data Interchange Standards Consortium (CDISC) specifications for the Exchange of Nonclinical Data (SEND) and Human Clinical Data (SDTM).

Our
Resources

Our Resources

Globally Harmonized Labs

ELISpot-Antigen Specific Response Assays

Biomarker Assay List

Scroll to Top

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

Patrick Bennett

Chief Executive Officer

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.